1. Greece Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Lavipharm SA

Lavipharm SA

AATHEX:LAVI
1.47
EUR
-0.03
(-1.87%)
134.11MMarket Cap
Mar 03Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.74
1.86
1.84
2.06
2.33
1.81
0.28
0.31
0.37
- -
Basic EPS, GAAP
0.71
0.07
0.29
0.11
0.1
0.04
0.01
0.05
0.04
- -
Free Cash Flow per Basic Share
0.04
0.02
0.03
0.08
0.13
-1.5
-0.02
-0.03
0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.02
- -
Book Value per Share
-1.09
-1.07
-0.79
-0.64
-0.55
0.24
0.25
0.31
0.33
0.31
Tangible Book Value per Share
-1.26
-1.21
-0.97
-0.83
-0.72
-0.04
-0.01
0.02
0.04
0.02
Basic Weighted Avg Shares
18
18
18
18
17
22
168
168
168
169
Sales/Revenue/Turnover
32
34
34
38
40
39
48
53
63
- -
Operating Margin (%)
9.26
14.42
13.54
13.57
13.55
9.56
9.6
10.34
14.39
- -
Depreciation Expense
2
1
1
2
2
2
4
5
5
- -
Net Income, GAAP
13
1
5
2
2
1
2
9
6
- -
Effective Tax Rate (%)
- -
56.27
- -
36.6
37.1
57.95
38.77
- -
32.69
- -
Profit Margin (%)
40.64
3.67
15.86
5.56
4.34
2.14
3.91
16.96
9.56
- -
Working Capital
- -
4
4
5
-15
- -
10
6
9
6
LT Debt
40
38
38
35
15
15
24
22
21
22
Total Equity
-20
-19
-14
-12
-10
40
43
53
56
53
Return on Invested Capital (%)
- -
8.17
- -
11.93
10.15
3.01
3.97
- -
7.08
- -
Return on Capital (%)
- -
9.92
- -
12.37
10.52
2.92
4.2
- -
8.21
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
4.51
18.77
10.94
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
9
9
11
LT Borrowings
13
12
12
LT Finance Leases
11
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
168
168
169
Market Capitalization
134
142
134

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
46
47
45
Cash, Cash Equivalents & STI
8
9
6
Accounts Receivable, Net
22
17
16
Inventories
15
17
19
Total Current Liabilities
36
38
39
Payables & Accruals
- -
- -
- -
ST Debt
9
9
11
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-96.78%
6.51%
Free Cash Flow
- -
-341.8%
-140.91%
Net Income, GAAP
- -
80.34%
-33.36%
Sales/Revenue/Turnover
- -
11.04%
18.2%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
48
2024
- -
- -
53
2025
- -
- -
63

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
0.05
2025
- -
- -
0.04

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
0.02

Company Description

Company Profile APIChatGPT
CEO
Telemaque Jean Lavidas
Full Time Employees
285
Sector
Health technology
Industry
Pharmaceuticals: major
Address
12, Agias Marinas Street Paiania GI Greece 19002
IPO Date
Nov 8, 1995
Website
lavipharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Lavipharm S.A. is a pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of pharmaceutical products and healthcare solutions. Its core product portfolio includes prescription medicines, over-the-counter (OTC) pharmaceuticals, branded generics, and consumer health products. The company offers a diverse range of pharmaceutical formulations such as tablets, capsules, injectable solutions, syrups, and topical products. Lavipharm operates mainly in Greece and the broader Southeastern European region, focusing on serving healthcare providers, pharmacies, and end consumers. Founded in 1911, the company is headquartered in Athens, Greece. In recent years, Lavipharm has undertaken strategic initiatives to expand its product offerings and strengthen its market presence. While explicit detailed major changes for 2024-2025 were not publicly highlighted, Lavipharm is known to consistently evolve through new product launches in the pharmaceutical and healthcare segments and has shown ongoing commitment to partnerships and collaborations within the industry to support growth and innovation. Its focus remains on enhancing its portfolio with effective medicines and consumer health products to meet regional healthcare demands and regulatory standards. Lavipharm's operations span research and development, manufacturing, and distribution, aligning with its mission to provide quality healthcare solutions. It serves various therapeutic areas including cardiovascular, central nervous system, antibiotics, and dermatology. The company also manages subsidiary relationships and adapts to regulatory environments within its geographic footprint to maintain compliance and competitiveness. As a long-established firm, Lavipharm continuously invests in innovation and development to adapt to evolving healthcare needs in its target markets.